Pharma firms set to bring international drugs to India for niche therapies

The diagnostics market is estimated to be 7-8% of the drugs business

India might be the largest supplier of generic drugs to the United States, some homegrown healthcare and pharma firms, however, have off late woken up to the opportunity of bringing in international drugs to India for niche therapies. 

Ahmedabad-based Sundyota Numandis Group has taken the licensing route to bring in clinically proven products in probiotics, pharmabiotics, nutraceuticals and phytopharmaceuticals (sourced from botanical extracts) from international firms and then launch them under their own brands in India. 

Sundyota has also tied up with leading pharma players like Abbott India, Zydus Cadila, Alkem, Cipla, USV Pharma, Mankind Pharma, Ajanta Pharma, Eris Lifesciences